02630 旺山旺水－Ｂ
VIGONVITA-B
VIGONVITA-B
| Listing Date | 2025/11/06 |
| Listing Price | 33.370 |
Quote
Subscription Result
- Subscription Rate6,238.42x
- Guarantee One Lot Size--
- One Lot Success Rate1.68%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Vigonvita Life Sciences Co. was founded in 2013, the Group is a biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of small-molecule drugs in its strategically focused therapeutic areas, namely, neuropsychiatry, reproductive health, and viral infection.
--
The Group have acquired and developed two Core Products, LV232 and TPN171. LV232 is a dual-target serotonin transporter/5-hydroxytryptamine 3 receptor modulator for the treatment of major depressive disorder, and TPN171 is a type-5 phosphodiesterase inhibitor for the treatment of erectile dysfunction. The Group also have four candidates in clinical stage and three candidates in pre-clinical stage.
--
The Group have established a GMP-standard commercial-scale in-house manufacturing facility located in Lianyungang, Jiangsu Province, with an aggregate GFA of approximately 51,955 sq.m. and an annual designed manufacturing capacity of 100 million capsules and 600 million tablets.
--
The Group’s customers primarily consist of its out-licensing customers, as well as its direct sales customers and distributors which directly purchase pharmaceutical products from it, as well as pharmaceutical companies to which it provides CRO services. The Group held 79 issued patents and 97 patent applications.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 17.60M H shares |
| No. of International Offer Shares | 15.84M H shares |
| No. of HK Offer Shares | 1.76M H shares |
| Offer Price | $32.00 - $34.00 |
| Stock Code | 2630 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, ABCI Securities Company Limited, China Galaxy International Securities (Hong Kong) Co., Limited, CCB International Capital Limited, China Everbright Securities (HK) Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Zhongtai International Securities Limited |
TIME TABLE
| Application Period | Oct 28 (Tue) - noon, Nov 03 (Mon) |
| Price Determination Date | Nov 04 (Tue) |
| Result Announcement Date | On or before Nov 05 (Wed) |
| Result Announcement Date | On or before Nov 05 (Wed) |
| Result Announcement Date | On or before Nov 06 (Thu) |
| Dealings in Shares commence on | Nov 06, 2025. (Thu) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $32.00 - $34.00 |
| Capitalization | 5.36B - 5.70B |
| NAV / share ($) | $3.23 - $3.44 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 33.0, the net proceeds raised would be HKD 521.10M, of which |
| 38% : Research and development of Core Products |
| 27% : Research and development of other product candidates |
| 10% : Construction of Qingdao Facility |
| 15% : Reinforcement of sales and marketing capabilities |
| 10% : Working capital |
IPO NEWS
| 06/11/2025 16:09 |
| {New Stock}VIGONVITA-B(02630) ends up 145.73% at HK$82 |
| 06/11/2025 09:20 |
| {New Stock}VIGONVITA-B(02630) opens up 184.69% at HK$95 |
| 05/11/2025 18:35 |
| {New Stock}VIGONVITA-B(02630) ends up 154.72% on grey market |
| 05/11/2025 16:20 |
| {New Stock}VIGONVITA-B up 139.74% at HK$80 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).